Ashlins Pharmaceuticals has licensed ex-China rights to develop products using Lee’s Pharm’s interferon alpha-2b API in a deal worth up to $31 million. The rare disease startup now plans to raise about $50 million and believes the funding could take
The U.S. Food and Drug Administration has expanded the indication of Tzield, developed by Sanofi SA, to include children and adolescents aged 8 to 17 who have recently been diagnosed with stage 3 type 1 diabetes. This update broadens the
